Boothbay Fund Management’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
Other funds holding ALDX
PA
KCM
EAM
LCM
Boothbay Fund Management's ALDX Position: Q2 2023 in Review
Boothbay Fund Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 16,521 shares — an estimated $164K sold.
Boothbay Fund Management first reported a position in ALDX in Q4 2018 and held it in 9 quarters. The position peaked at $1.24M in Q1 2019. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.
- Boothbay Fund Management reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
- Boothbay Fund Management sold 16,521 Aldeyra Therapeutics shares in Q2 2023, an estimated $164K.
- Boothbay Fund Management first reported a position in Aldeyra Therapeutics in Q4 2018 and held it in 9 quarters.
- Boothbay Fund Management's Aldeyra Therapeutics position peaked at $1.24M in Q1 2019.
- 119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.
Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.